What is Foundayor (Orfoglipron)? The world's first GLP-1 drug that can be taken regardless of meals.

What is Foundayo (orforglipron)?

Foundayo is an oral small-molecule GLP-1 receptor agonist developed by Eli Lilly. Its origins are said to be a compound that Chugai Pharmaceutical, a Japanese company, was involved in during the initial development phase, after which global development and approval were pursued. On April 1, 2026, the U.S. FDA approved it as a treatment for obesity, and it is marketed under the brand name "Foundayo."

The key is its "small-molecule, non-peptide type" nature

Conventional oral GLP-1 drugs like Rybelsus (semaglutide) have a peptide structure, making them difficult to absorb, and requiring strict rules for administration: taking it immediately upon waking, on an empty stomach, and with only a small amount of water. Foundayo, being a "small-molecule" compound without a peptide structure, has its biggest advantage in that it can be taken regardless of meal timing or the amount of water, which is its greatest feature.

Differences from Rybelsus

Effects observed in clinical trials

The efficacy of Foundayo has been confirmed in two Phase 3 clinical trial programs: the "ATTAIN" trial for obesity and the "ACHIEVE" trial for type 2 diabetes.

While a slightly smaller weight loss was reported for individuals with type 2 diabetes (ATTAIN-2) compared to those without diabetes (ATTAIN-1), both groups showed statistically significant weight loss compared to the placebo group.

How to increase the dose

To minimize gastrointestinal symptoms, the design involves gradually increasing the dose from a small amount. In clinical trials (ATTAIN-1), the dose was increased in steps every four weeks: 1mg → 3mg → 6mg → 12mg → 24mg → 36mg. When prescribing at our clinic, we plan to gradually increase the dose while monitoring the patient's condition.

About side effects

• Gastrointestinal symptoms such as nausea, diarrhea, and constipation (similar to other GLP-1 drugs, these tend to appear early during dose escalation)

• Hypoglycemia (caution when used in combination with other diabetes medications)

• To date, clinical trials have not reported any clear signals of adverse effects on liver function.

• While the frequency of serious side effects is not considered high, a certain number of cases have been reported where treatment was discontinued due to side effects.

Recommended for:

• Those who are resistant to injections

• Those who find it difficult to follow Rybelsus's administration rules (empty stomach, small amount of water)

• Those who frequently eat out or have irregular meal times and desire flexibility in dosing times

• Those who want to maintain weight after losing it with injectable drugs like Mounjaro or Ozempic, by switching to an oral medication

About the prospect of approval in Japan

As of July 2026, Foundayo (orforglipron) is not approved in Japan. While there are reports that following its approval in the US, launches are expected in China, Europe, and the UK from late 2026 to 2027, the approval timeline for Japan is currently not clear. Our clinic plans to offer it as an imported medication under self-pay medical care during the period before domestic approval (we will announce the official start date separately).

Online treatment flow

• ① Provisional payment / Pre-consultation: Select your desired plan and place an order

• ② Online consultation: A doctor will confirm suitability via video call

• ③ Shipping as early as the same day

• ④ Follow-up on progress with regular consultations, adjusting dosage as needed

References

• Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med. 2025;393(18):1796-1806.

• Jastreboff AM, et al. Oral orforglipron for the treatment of obesity and type 2 diabetes (ATTAIN-2). N Engl J Med. 2025.

• Frias JP, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877-888.